tiprankstipranks
Advertisement
Advertisement

VRCA Stock Latest News

Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV
Company AnnouncementsVerrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV
5d ago
VEEV
VRCA
Verrica Shareholders Approve Governance Measures at Annual Meeting
PremiumCompany Announcements
Verrica Shareholders Approve Governance Measures at Annual Meeting
5d ago
8K
VRCA
Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright
20d ago
VRCA
Verrica Pharmaceuticals Earnings Call Highlights Growth, Strain
PremiumCompany Announcements
Verrica Pharmaceuticals Earnings Call Highlights Growth, Strain
1M ago
VRCA
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
PremiumThe Fly
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)
1M ago
VRCA
Verrica Pharmaceuticals: Focused Ycanth Rollout and Underpenetrated Pediatric Market Drive Attractive Risk‑Reward and Support Buy Rating
PremiumRatingsVerrica Pharmaceuticals: Focused Ycanth Rollout and Underpenetrated Pediatric Market Drive Attractive Risk‑Reward and Support Buy Rating
3M ago
VRCA
Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)
Premium
The Fly
Verrica Pharmaceuticals reports Q4 adjusted EPS (51c), consensus (79c)
3M ago
VRCA
Verrica Pharmaceuticals (VRCA) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Verrica Pharmaceuticals (VRCA) Q4 Earnings Cheat Sheet
3M ago
VRCA
Five new option listings and fourteen option delistings on February 23rd
PremiumThe Fly
Five new option listings and fourteen option delistings on February 23rd
4M ago
PHB
PIN
Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer
PremiumThe Fly
Verrica Pharmaceuticals appoints Chapman as Chief Commercial Officer
4M ago
VRCA
Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
PremiumThe Fly
Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
4M ago
VRCA
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
PremiumCompany Announcements
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
5M ago
VEEV
VRCA
Verrica announces first patient dosed in program evaluating YCANTH
PremiumThe FlyVerrica announces first patient dosed in program evaluating YCANTH
5M ago
VRCA
Verrica Pharmaceuticals Adds Caligan Partner to Board
Premium
Company Announcements
Verrica Pharmaceuticals Adds Caligan Partner to Board
6M ago
8K
VRCA
Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline
Premium
The Fly
Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline
6M ago
VRCA
Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
PremiumThe Fly
Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
6M ago
VRCA
Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns
PremiumRatings
Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns
7M ago
VRCA
Verrica Pharmaceuticals Secures $50M Financing Deal
PremiumCompany Announcements
Verrica Pharmaceuticals Secures $50M Financing Deal
7M ago
8K
VRCA
Verrica Pharmaceuticals announces private placement financing of $50M
PremiumThe Fly
Verrica Pharmaceuticals announces private placement financing of $50M
7M ago
VRCA
Verrica Pharmaceuticals Reports Strong Growth Amid Challenges
PremiumCompany AnnouncementsVerrica Pharmaceuticals Reports Strong Growth Amid Challenges
7M ago
VRCA
Verrica Pharmaceuticals Reports Q3 2025 Earnings
Premium
Company Announcements
Verrica Pharmaceuticals Reports Q3 2025 Earnings
7M ago
VRCA
Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)
Premium
The Fly
Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)
7M ago
VRCA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >